To study safety, tolerability and pharmacokinetics of AZD1305 in healthy male Japanese subjects
Study identifier:D3191C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A single-centre, single-blind, randomised, placebo-controlled, phase I study to assess the safety, tolerability and pharmacokinetics after single ascending intravenous doses of AZD1305 in healthy male Japanese subjects
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD1305, Placebo
Sex
Male
Actual Enrollment
36
Study type
Interventional
Age
20 Years - 40 Years
Date
Study Start Date: 01 Jul 2008
Primary Completion Date: -
Study Completion Date: 01 Oct 2008
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD1305 Solution for iv infusion, single dose |
| Placebo Comparator: 2 | Drug: Placebo NaCl solution for iv infusion, single dose |
Contacts
Investigators
Principal Investigator
Helen Lunde
AstraZeneca R&D Mölndal, Sweden
